BlossomHill Therapeutics, Inc.
No SEC Form 4 filings for $BLSM in the last 30 days.
BlossomHill Therapeutics, Inc. (BLSM) priced its Nasdaq IPO at $16 per share, raising $150 million. J.P. Morgan and Leerink led the book. The company is a precision oncology developer, and the IPO pricing provides a test of current biotech IPO conditions.
BlossomHill Therapeutics Inc. (NASDAQ:BLSM) shares fell 1.6% in their trading debut after the oncology-focused biotech raised $150 million in an upsized U.S. IPO. The stock opened at $15.75 versus a $16 IPO price, with 9.375 million shares priced at $16. Gross proceeds were expected at $150.0 million, and the firm valued around $482.6 million.
BlossomHill Therapeutics priced its IPO at $16.00 per share, selling 9,375,000 shares to raise about $150.0 million in gross proceeds, according to the company’s Aug. 6, 2026 press release. The offering was upsized and includes a 30-day option for 1,406,250 more shares. Shares are set to trade on Nasdaq as BLSM on Aug. 7, 2026.
Over the past 7 days, alphai's AI scored 3 news stories mentioning BLSM (BlossomHill Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 3 neutral, and 0 bearish.
The IPO pricing and size are the primary tradable catalyst for BLSM, setting initial float and near-term liquidity expectations.
IPO pricing and first-day trading provide an immediate read on demand and near-term sentiment for BLSM.
IPO pricing and first-trade setup can drive near-term volatility and liquidity dynamics for BLSM, but there is no operating update beyond the capital raise.
alphai scores every news story that mentions BLSM with an AI model for sentiment and relevance, and aggregates insider trades from BlossomHill Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BlossomHill Therapeutics, Inc. (BLSM) priced its Nasdaq IPO at $16 per share, raising $150 million. J.P. Morgan and Leerink led the book. The company is a precision oncology developer, and the IPO pricing provides a test of current biotech IPO conditions.
2 min readBlossomHill Therapeutics Inc. (NASDAQ:BLSM) shares fell 1.6% in their trading debut after the oncology-focused biotech raised $150 million in an upsized U.S. IPO. The stock opened at $15.75 versus a $16 IPO price, with 9.375 million shares priced at $16. Gross proceeds were expected at $150.0 million, and the firm valued around $482.6 million.
3 min readBlossomHill Therapeutics priced its IPO at $16.00 per share, selling 9,375,000 shares to raise about $150.0 million in gross proceeds, according to the company’s Aug. 6, 2026 press release. The offering was upsized and includes a 30-day option for 1,406,250 more shares. Shares are set to trade on Nasdaq as BLSM on Aug. 7, 2026.
2 min read
